دورية أكاديمية

Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma.

التفاصيل البيبلوغرافية
العنوان: Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma.
المؤلفون: Han, Dale, Han, Gang, Zhao, Xiuhua, Rao, Nikhil G., Messina, Jane L., Marzban, Suroosh S., Sarnaik, Amod A., Cruse, C. Wayne, Sondak, Vernon K., Zager, Jonathan S.
المصدر: PLoS ONE; Mar2015, Vol. 10 Issue 3, p1-12, 12p
مصطلحات موضوعية: CLINICAL trials, RETROSPECTIVE studies, HEALTH outcome assessment, HISTOPATHOLOGY, MULTIVARIATE analysis
مستخلص: Background and Objectives: Desmoplastic melanoma is a unique subtype of melanoma which typically affects older patients who often have comorbidities that can adversely affect survival. We sought to identify melanoma-specific factors influencing survival in patients with desmoplastic melanoma. Methods: Retrospective review from 1993 to 2011 identified 316 patients with primary desmoplastic melanoma. Clinicopathologic characteristics were correlated with nodal status and outcome. Results: Fifty-five patients (17.4%) had nodal disease: 33 had a positive sentinel lymph node biopsy and 22 developed nodal recurrences (no sentinel lymph node biopsy or false-negative sentinel lymph node biopsy). Nodal disease occurred more often in younger patients and in cases with mixed compared with pure histology (26.7% vs. 14.6%); both of these variables significantly predicted nodal status on multivariable analysis (p<0.05). After a median follow-up of 5.3 years, recurrence developed in 87 patients (27.5%), and 111 deaths occurred. The cause of death was known in 79 cases, with 47 deaths (59.5%) being melanoma-related. On multivariable analysis, Breslow thickness, mitotic rate ≥1/mm2 and nodal status significantly predicted melanoma-specific survival (p<0.05). Conclusions: Nodal status predicts melanoma-specific survival in patients with desmoplastic melanoma. However, since patients with desmoplastic melanoma represent an older population, and a considerable proportion of deaths are not melanoma-related (40.5%), comorbidities should be carefully considered in making staging and treatment decisions in this population. [ABSTRACT FROM AUTHOR]
Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:19326203
DOI:10.1371/journal.pone.0119716